Efficacy and Safety of 8 mg Aflibercept in PULSAR Extension

Patients who switched from 2 mg to 8 mg maintained their vision and extended time between treatments with no vasculitis or other retinal occlusive events.

By: Tien Wong, MD, PhD, Michael A. Singer, MD

Retinal Physician February 24, 2025

Clinical Report: Efficacy and Safety of 8 mg Aflibercept in PULSAR Extension

Overview

The PULSAR extension trial demonstrated that patients switching from 2 mg to 8 mg aflibercept maintained vision and extended treatment intervals without significant safety concerns. The study supports the use of high-dose aflibercept for neovascular age-related macular degeneration (AMD) over a three-year period.

Background

Neovascular age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, necessitating effective treatment strategies. Aflibercept, an anti-VEGF therapy, has been pivotal in managing this condition. The PULSAR extension trial provides critical insights into the long-term efficacy and safety of high-dose aflibercept, which could influence treatment protocols.

Data Highlights

No numerical data available.

Key Findings

Rephrase to ensure clarity and accuracy, possibly breaking down complex findings into simpler statements.

Clinical Implications

The findings suggest that clinicians may consider switching patients from 2 mg to 8 mg aflibercept to enhance treatment intervals and maintain visual acuity. This approach could reduce the treatment burden for patients with neovascular AMD.

Conclusion

The PULSAR extension trial reinforces the efficacy and safety of high-dose aflibercept, offering a viable treatment option for patients with neovascular AMD. Further research may solidify its role in clinical practice.

PentaVision

Retinal Physician